Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TELA Bio (TELA) Change in Receivables (2018 - 2025)

Historic Change in Receivables for Bio (TELA) over the last 8 years, with Q3 2025 value amounting to $107000.0.

  • Bio's Change in Receivables fell 9467.13% to $107000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $59000.0, marking a year-over-year decrease of 9823.72%. This contributed to the annual value of $762000.0 for FY2024, which is 7508.18% down from last year.
  • According to the latest figures from Q3 2025, Bio's Change in Receivables is $107000.0, which was down 9467.13% from $533000.0 recorded in Q2 2025.
  • In the past 5 years, Bio's Change in Receivables ranged from a high of $2.0 million in Q3 2024 and a low of -$983000.0 during Q4 2024
  • Its 5-year average for Change in Receivables is $465052.6, with a median of $402000.0 in 2025.
  • As far as peak fluctuations go, Bio's Change in Receivables skyrocketed by 150243.9% in 2021, and later plummeted by 16136.08% in 2024.
  • Over the past 5 years, Bio's Change in Receivables (Quarter) stood at $657000.0 in 2021, then soared by 35.46% to $890000.0 in 2022, then soared by 80.0% to $1.6 million in 2023, then tumbled by 161.36% to -$983000.0 in 2024, then skyrocketed by 110.89% to $107000.0 in 2025.
  • Its Change in Receivables was $107000.0 in Q3 2025, compared to $533000.0 in Q2 2025 and $402000.0 in Q1 2025.